Alpha-1 Antitrypsin Deficiency (AATD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Alpha-1 Antitrypsin Deficiency (AATD) Market Outlook

Thelansis’s “Alpha-1 Antitrypsin Deficiency (AATD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alpha-1 Antitrypsin Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Alpha-1 Antitrypsin Deficiency (AATD) Overview

Alpha-1 Antitrypsin Deficiency (AATD) is a hereditary condition, often overlooked, characterized by low circulating alpha-antitrypsin (AAT) in the bloodstream. This condition presents as hepatic dysfunction from infancy through adulthood and chronic obstructive lung disease (specifically emphysema or bronchiectasis) in individuals over 30. People with AATD also face an elevated risk of panniculitis and C-ANCA-positive vasculitis. The expression of these symptoms can vary among individuals and families. In adults, smoking is the primary factor accelerating the development of chronic obstructive pulmonary disease (COPD). However, nonsmokers with AATD can still develop lung and liver issues and have an average life expectancy. Emphysema in children with AATD is exceedingly rare. AATD-related liver disease, seen in only a small fraction of affected children, typically presents as neonatal cholestasis. The incidence of liver disease increases with age, and adults may develop cirrhosis and fibrosis without a history of neonatal or childhood liver issues. Additionally, individuals with AATD are at an increased risk of hepatocellular carcinoma (HCC).

• The prevalence of alpha-1 Antitrypsin Deficiency (AATD) ranges from 1 to 2 cases per 10,000 population in the USA. 

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: